Cogent Biosciences (COGT) Profit After Tax (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Profit After Tax data on file, last reported at -$97.4 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 34.71% year-over-year to -$97.4 million in Q1 2026; TTM through Mar 2026 was -$354.3 million, a 72.59% decrease from a year earlier, with the FY2025 full-year figure at -$328.9 million, down 28.55% from the prior year.
• Profit After Tax for Q1 2026 stood at -$97.4 million, up from -$102.5 million in the prior quarter.
• Over the last five years, Profit After Tax for COGT reached as high as -$3.4 million in Q4 2024 and fell as low as -$102.5 million in Q4 2025.
• Historically, Profit After Tax has averaged -$54.1 million across 5 years, with a median of -$58.3 million in 2024.
• Across the five-year window, Profit After Tax jumped 72.16% in 2023 and tumbled 2877.92% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$39.5 million in 2022, then slipped by 14.84% to -$45.3 million in 2023, then soared by 92.4% to -$3.4 million in 2024, then tumbled by 2877.92% to -$102.5 million in 2025, then increased by 5.02% to -$97.4 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$97.4 million in Q1 2026, -$102.5 million in Q4 2025, and -$80.9 million in Q3 2025.